Literature DB >> 3297714

Priming reduces the bone marrow toxicity of carboplatin.

M E Gore, C A Hills, Z H Siddik, J P Sloane, A R Winkley, I E Smith, J L Millar.   

Abstract

A dose of 170 mg/kg of carboplatin is lethal in mice, death occurring through bone marrow failure. This lethality can be avoided by giving the animals 200 mg/kg cyclophosphamide 1 or 2 days before this dose of carboplatin. The improved normal tissue tolerance cannot be explained by altered pharmacokinetics of carboplatin. Increased survival appears to be associated with a more rapid regeneration of the haemopoietic stem cells. Tumour tissue is not protected in the same way and thus a therapeutic gain can be achieved using this protocol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297714     DOI: 10.1016/0277-5379(87)90422-6

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  2 in total

1.  Bullatacin--in vivo and in vitro experience in an ovarian cancer model.

Authors:  C H Holschneider; M T Johnson; R M Knox; A Rezai; W J Ryan; F J Montz
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 2.  Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.

Authors:  A J Wagstaff; A Ward; P Benfield; R C Heel
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.